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Abstract  
 
The fatal X-linked Duchenne muscular dystrophy (DMD), characterized by progressive muscle 
wasting and muscle weakness, is caused by mutations within the DMD gene. The use of 
antisense oligonucleotides (AOs) modulating pre-mRNA splicing to restore the disrupted 
dystrophin reading frame, subsequently generating a shortened but functional protein has 
emerged as a potential strategy in DMD treatment. AO therapy has recently been applied to 
induce out-of-frame exon skipping of myostatin pre-mRNA, knocking-down expression of 
myostatin protein, and such an approach is suggested to enhance muscle 
hypertrophy/hyperplasia and to reduce muscle necrosis. Within this study, we investigated dual 
exon skipping of dystrophin and myostatin pre-mRNAs using phosphorodiamidate morpholino 
oligomers conjugated with an arginine-rich peptide (B-PMOs). Intraperitoneal administration of 
B-PMOs was performed in neonatal mdx males on the day of birth, and at weeks 3 and 6. At 
week 9, we observed in treated mice (as compared to age-matched, saline-injected controls) 
normalization of muscle mass, a recovery in dystrophin expression, and a decrease in muscle 
necrosis, particularly in the diaphragm. Our data provide a proof of concept for antisense 
therapy combining dystrophin restoration and myostatin inhibition for the treatment of DMD. 
 
Keywords: Duchenne muscular dystrophy, antisense oligonucleotides, exon skipping, 
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Introduction  
 
Duchenne muscular dystrophy (DMD) is a recessive X-linked muscle disease, affecting 1 in 
3500 live male births. Almost 30 years since the discovery of the DMD gene1, there has been no 
cure for this fatal disorder. Current treatments have shown alleviation in the dystrophinopathic 
symptoms but failed in halting the disease progression. Gene therapy-based studies, in 
particular an approach using antisense oligonucleotides (AOs), however, have recently held 
promise for DMD patients. This therapy uses small oligonucleotides to correct frame-shifting or 
nonsense mutations of the DMD gene by skipping a mutated exon or exons which disrupt the 
reading frame in such a way that it restores the reading frame of the dystrophin transcript, 
leading to synthesis of shortened but functional dystrophin protein. Encouraging results have 
been demonstrated in murine2,3 and canine models4 of DMD and have been translated into 
clinical trials5–7 with minor safety concern. However, clinical application so far has used either 
phosphorothioate morpholino oligomer (PMO) or 2′-O-methyl-phosphothioate (2'-OMePS) AO 
(clinicaltrials.gov identifiers NCT01254019, NCT01396239) that usually requires high and 
frequently repeated dosages due to poor cell uptake and rapid renal clearance of the AOs5. 
Importantly, these AOs induced restoration of dystrophin expression in skeletal muscles but 
failed in cardiac tissue8, unless extremely high doses were used9, whilst cardiomyopathy is one 
of the two main reasons causing death in DMD. Researchers therefore have developed a new 
generation of AOs, conjugated to cell penetrating peptides, i.e. PMOs conjugated with an 
arginine-rich B peptide (BPMOs). Pre-clinical tests in DMD mouse models have demonstrated 
therapeutic effects of BPMOs were far more efficient than of unconjugated PMOs when used at 
the same dose10, and interestingly with dystrophin expression in body-wide skeletal plus cardiac 
muscles11. 
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Therapeutic benefits of antisense therapy-mediated dystrophin expression however depend on 
the severity of the disease at the time the treatment initiated. Indeed, depletion in the muscle 
fiber number, reduction in the muscle mass together with compromised integrity in the fiber 
structure and formation of muscle fibrosis in late stages of DMD cannot be targeted only by 
recovering dystrophin levels12. Hence, knocking-down expression of myostatin, a negative 
regulator of skeletal muscle growth and differentiation13 and an enhancer of the proliferation of 
muscle fibroblasts14, has been suggested as a potential adjunct therapy for DMD. We have 
initially published that AO-induced out-of-frame skipping of myostatin stimulated hypertrophy in 
treated tibialis anterior muscles of wild-type mice15. We and others have further investigated 
dual skipping of dystrophin and myostatin in mouse and human dystrophic cells16 and in a mdx 
mouse model of DMD10, confirming the efficacy of the combined antisense therapy with no 
interference between the two AOs. However, BPMO-induced exon skipping levels of myostatin 
in treated mice were 4-5 times lower than of dystrophin although both BPMOs were used at the 
same dose, resulting in no significant difference in the therapeutic effects between single and 
dual treatments. A tentative explanation for such failure can be that the treatment started 6 
weeks after animal birth, rather than at birth, when negative effects of the disease began to 
accumulate17,18, reducing or interfering with the therapeutic benefit. A possible inadequate dose 
of BPMO-myostatin is an additional reason for the lack of success. To circumvent this, we 
investigated the effects of a dual exon skipping approach in neonatal mdx through regular 
systemic administration of the BPMOs. As expected, the intervention at very early stage of the 
disease enhanced the therapeutic benefit. This study importantly established that AO-mediated 
downregulation of myostatin expression can be a synergistic therapy with AO-induced 
restoration of dystrophin level for the treatment of DMD. 
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Results 
 
RT-PCR demonstrating skipping of dystrophin and myostatin pre-mRNAs 
 
In order to confirm our previous findings10 and to further enhance the therapeutic benefits of 
antisense oligonucleotide (AO)-induced dual exon skipping of dystrophin and myostatin pre-
mRNAs, we investigated here a combined therapy in p0 mdx mice through regular 
intraperitoneal injection. Mdx neonates were injected with 10 mg/kg of BPMO-DMD (n = 7) or a 
mixture of BPMO-DMD and BPMO-MSTN, 10 mg/kg each BPMO (n = 6). After three injections 
on day 0, weeks 3 and 6, the diaphragm (DIA) and four skeletal muscles, including the extensor 
digitorum longus (EDL), gastrocnemius (GAS), soleus (SOL), and tibialis anterior (TA), were 
collected. RNA extraction and subsequent RT-PCRs were performed. Representative PCR 
products (Fig. 1d) indicated efficient skipping of DMD exon 23 (or both exons 22 and 23) in all 
examined tissue. A further analysis clarified the skipping levels of dystrophin pre-mRNA were in 
a range of 16-78%, with the highest value in the diaphragm (78.4 ± 6.6%), (Fig. 1a). We 
observed no statistical difference in the skipping efficiency between BPMO-DMD administered 
alone and in combination with BPMO-MSTN, at individual muscle level (Fig. 1a) or at systemic 
level (Fig. 1b), suggesting no interference between the two oligomers in the dual therapy. 
Skipping levels of myostatin, however, was three-fold less than those of dystrophin. The highest 
skipping at 28.7 ± 10.2% was detected in the soleus whereas surprisingly the diaphragm 
displayed the lowest skipping at 4.6 ± 2.1% (Figs. 1c, e). Our results demonstrated initial effects 
of the antisense treatment although with a variability in the skipping levels possibly due to 
systemic i.p administration of the BPMOs.  
 
Substantial expression of dystrophin in the diaphragm of BPMO-injected mdx 
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As described in the previous section DIA, GAS, and TA muscles were harvested from treated 
mdx mice. The amount of dystrophin within these muscles was then evaluated by Western 
Blotting, with detectable expression observed in only the diaphragm (Fig. 2a). Subsequent 
quantification of dystrophin expression, in comparison with C57 control samples (considered as 
100%), confirmed 15.7 ± 6.2% and 43.7 ± 19.4% dystrophin presented in BPMO-DMD- and 
BPMO-DMD & -MSTN-treated muscle, respectively (Fig. 2b). Although the level of dystrophin 
from mdx receiving the combined treatment appeared three times higher than that from BPMO-
DMD-injected group, statistical analysis confirmed no significant difference between the  two 
treatment sets (p = 0.17, two-tailed Student's t test). 
 
In addition to Western Blot quantification, dystrophin expression was ascertained by 
immunohistochemistry staining (Fig. 3). As expected, the intensity of dystrophin within C57 
samples was obvious whereas nearly no dystrophin-positive fibers were detected from saline-
injected mdx muscles. In BPMO-receiving groups, the levels of dystrophin intensity were 
variable among the five tissues assessed. However, dystrophin expression within diaphragm 
sections was the highest and comparable to C57 control samples. Hence, histological analysis 
provided consistent results with Western Blot quantification, suggesting that AO therapy in 
neonatal mdx effectively rescues dystrophin synthesis, predominantly in the diaphragm, maybe 
due to the administration route of the BPMOs. 
 
Antisense-mediated treatment ameliorated the pathology of DMD, significantly in the 
diaphragm  
 
Following encouraging results at transcriptional and translational levels, we investigated the 
therapeutic benefit of antisense therapy on the diaphragm at the cellular level. Laminin staining 
was used to reveal the perimeter, especially of dystrophic fibers (Fig. 4a). According to a 
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measurement of the minimal Feret's diameter of the fibers, a shift was observed in the 
distribution of BPMO-treated diaphragm fibers, reverting towards the wild-type of C57 fibers 
(Fig. 4b). A subsequent evaluation demonstrated a significant reduction of 15% and 30% in the 
variance coefficient of the Feret's diameter of BPMO-DMD and BPMO-DMD & -MSTN groups, 
respectively, as compared to saline-injected mdx (Fig. 4c). Nonetheless, such changes did not 
normalize to wild-type C57 controls. Since DMD is characterized as a muscle wasting disorder, 
the number of fibers within each diaphragm section was additionally quantified. In comparison to 
C57 samples, we observed a significant decrease only in the fiber number of non-treated mdx 
(p = 0.01, two-tailed Student's t test), (Fig. 4d). As further assessment of the effects on 
dystrophic muscles previously undergoing muscle degeneration and regeneration, we 
calculated the prevalence of fibers having centralized nuclei (as percentage of the total number 
of fibers) within each section (Fig. 4e). Healthy C57 muscle displayed less than 1% 
centronucleated fibers whilst as expected the percentage in untreated mdx muscle was 43.4 ± 
1.7%. This reduced to 27.2 ± 3.2% and 13.8 ± 3.0% after treatment with BPMO-DMD or BPMO-
DMD & -MSTN. Moreover, a statistical difference (p = 0.004, two-tailed Student's t test) between 
the two BPMO-treated groups was identified, with reduced centronucleation in the BPMO-DMD 
& -MSTN group. 
 
When this analysis was applied to the soleus muscle (where exon skipping of myostatin was 
most efficient among the five tissues assessed, which is possibly dependent on the fiber type) 
(Fig. 4f-j), surprisingly, the frequency distribution of the minimal Feret's diameter (Fig. 4g) and 
the variance coefficient values (Fig. 4h) in mdx groups (both treated and non-treated) were as 
comparable as those from C57. On the contrary, a significant drop in the total fiber number (Fig. 
4i) and a resulting high proportion of fibers having centralized nuclei (Fig. 4j) was seen in mdx 
muscles when compared to healthy controls. Among the mdx groups, the fiber values from 
BPMO-DMD group were not significantly different in comparison with those from BPMO-DMD & 
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-MSTN- or non-treated group whereas administration of BPMO-DMD & -MSTN provided an 
obvious reduction in the percentage of centrally nucleated fibers, as compared to non-treated 
mdx. Hence, the data from histological analysis confirmed the therapeutic effects of these 
antisense therapies. AO-induced exon skipping restoration of the reading frame of dystrophin 
pre-mRNA ameliorated the pathology of DMD. The benefit, moreover, was significantly 
enhanced when combined with destructive exon-skipping inhibition of myostatin.  
 
Effects of antisense therapy on body and muscle mass 
 
Neonatal mdx males received either 10 mg/kg of BPMO-DMD (n = 7) or a combination of 10 
mg/kg BPMO-DMD and 10 mg/kg BPMO-MSTN (n = 6) on day 0, week 3 and week 6. The body 
weight was recorded every 2 weeks and was normalized to the birth weight (Figs. 5a, b). Four 
weeks following the first injection, we observed some changes in treated mdx mice compared 
with saline-injected age-matched mdx (n = 4) or C57 (n = 5) subjects. However, from week 6 
onwards, mdx mice (regardless of the treatment) displayed similar weight gain. 
 
All mice were sacrificed at week 9. The mass of five muscle types, including DIA, EDL, GAS, 
SOL, and TA were evaluated (Fig. 5c). In all tissues examined, muscle mass from mdx mice, 
both treated and non-treated, was heavier than that from wild-type animals. Nevertheless, after 
being normalized to the final body weight, the differences were observed in only large muscles, 
i.e. DIA, GAS, and TA (Fig. 5d). Significant changes between BPMO-treated mdx and non-
treated mdx or C57 were seen, although limited, in the DIA (Figs. 5c, d). A further analysis of 
the locomotor behavior of BPMO-injected animals demonstrated significantly normalized 
dystrophic phenotype of the mdx mice relative to the C57 controls, i.e. total mobile counts, static 
time (Table. S1). These results ascertain the effects of AO therapy and provide a support for the 
treatment combining rescue of dystrophin and knockdown of myostatin.   
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Discussion 
 
Following our previous encouraging findings10,15, we investigated the effect of antisense-
mediated dual exon skipping of dystrophin and myostatin pre-mRNAs in neonatal mdx mice. 
After three triweekly injections, we detected exon skipping of dystrophin (16-78%) and myostatin 
(5-29%) in all examined BPMO-treated muscles despite a high variability in the skipping level 
between muscle types and between subjects receiving the same treatment. A corresponding 
enhanced dystrophin expression of 16-44% (compared with wild-type control) was quantified by 
Western blotting, and was ascertained by immunohistochemistry analysis. This led to muscle 
normalization towards the wild-type properties indicated by reduced disorganized fiber structure 
and fiber centronucleation. Such promising results were predominantly seen in the diaphragm, 
with better effect seen in the group receiving both BPMO-DMD and -MSTN. Our data provide a 
strong support for antisense therapy combining dystrophin restoration and myostatin inhibition 
for the treatment of DMD. 
 
Among gene therapy-based approaches, which are potential treatments for DMD, antisense-
induced exon skipping restoring the reading frame of dystrophin and the consequent dystrophin 
protein level has been the most promising strategy so far. This approach is indeed the only 
gene therapy has entered phase III clinical trials for DMD. To date, however, there has been no 
study showing a complete rescue of dystrophin expression. Although a recovery over 20% of 
the normal dystrophin level (as we presented here) has been demonstrated to be sufficient to 
alleviate the dystrophic pathology, the lack of effect on muscle strength has remained a 
challenge19 which possibly depends on the stage (severity) of the disease when the treatment is 
applied12. Moreover, since the restored dystrophin protein is a truncated isoform with possibly a 
partial functionality, the therapy can only slow down not halt the disease progression. Hence, 
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there is a growing consensus that the treatment for DMD needs to address the faulty DMD gene 
together with other aspects of the disease, i.e. muscle fibrosis, muscle weakness.  
 
In this study, combining restoration of dystrophin level with knocking-down myostatin expression 
enhanced the therapeutic benefit as compared with recovering dystrophin expression alone. 
The effect was predominant in the diaphragm, which could be beneficial in ameliorating the 
respiratory aspect of DMD, and is possibly due to the route of the administration used. However, 
5% exon skipping of myostatin detected is not a strong evidence to support the positive effects 
of the combined treatment over the approach restoring dystrophin expression alone. We had 
reported10 that after a single intramuscular injection of AOs, exon skipping of myostatin was 
detected immediately but weakened from week 4 whereas at that time the muscle mass began 
to increase significantly. Hence, the low level of myostatin skipping here might be a residue of a 
sufficient level that has already been beneficial for the dystrophic muscle. Possible 
underestimation of the skipping efficiency of myostatin is also hypothesized. Unlike in-frame 
skipping of dystrophin restoring the reading frame, out-of-frame skipped myostatin mRNA is 
nonsense and may be degraded immediately by intracellular nucleases. Thereby, measuring 
the remaining skipped product might be an inaccurate assessment. Future analysis may 
consider a more reliable quantification, i.e. quantitative RT-PCR measuring the amount of full-
length myostatin mRNA followed by a subsequent comparison between treated and non-treated 
samples. 
 
Dumonceaux et al. (2010) have demonstrated that myostatin blockage led to muscle 
hyperplasia; or muscle hypertrophy when it was in combination with rescue of dystrophin 
expression. A substantial increase in muscle mass, muscle fiber diameter and contractile 
properties through down-regulation of myostatin has been also reported in other preclinical and 
clinical trials10,20–22. In contrast, we observed the body weight, muscle mass, and muscle 
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structure of treated mice normalized towards the wild-type properties. Indeed, an analysis at 
muscle level has indicated that knockdown of myostatin inhibited muscle degeneration and 
possibly thereby reduced muscle regeneration whilst no increase in muscle fiber size was 
detected. In regard to the body weight, within the first 4-6 weeks of the development mdx mice 
are believed to be as heavy as wild-type animals18. However, the mdx in our study were already 
significantly heavier than the controls at week 4; only those receiving BPMOs displayed a 
comparable weight with control mice. This result indicated that therapeutic benefit could be 
achieved as early as after 2 injections, and in particular when the treatment was applied at early 
stage of the disease. However, we observed no difference in body weight between treated and 
untreated mdx from week 6 onwards. This may be because at that time the muscle necrosis has 
reached its peak18 together with an effective innate muscle regeneration starting from weeks 3-
423 diminishing the therapeutic effect.  
 
It is yet unclear what level of contribution myostatin knockdown makes to differences seen in 
this study which contradict the effects reported in other studies. Further investigation into 
downregulation of myostatin in mdx mice needs to be carried out to clarify this and to improve 
its effect on body-wide muscles. Importantly, since the gene sequence and the protein function 
of myostatin are highly conserved across species24–27, promising findings reported here can be 
feasibly translated into clinical trials in conjunction with the current dystrophin therapy to 
improve the treatment for DMD.  
 
In summary, this study demonstrates antisense therapy ameliorates the pathology of DMD, 
significantly in the diaphragm, which is beneficial for combating the respiratory aspect of the 
disease. The effect of dual treatment combining recovery of dystrophin expression and inhibition 
of myostatin expression is more effective than that of rescuing dystrophin levels alone. We also 
show that an intervention in early stages of DMD (i.e. at birth) enhances the therapeutic 
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benefits. Our data together strongly support clinical application of dual antisense therapy in 
DMD treatment.  
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Materials and methods 
 
Antisense oligonucleotide preparation 
 
PMO-MSTN (5′-AGCCCATCTTCTCCTGGTCCTGGGAAGG-3′) and PMO-DMD (5′-
GGCCAAACCTCGGCTTACCTGAAAT-3′) that have been previously demonstrated to be 
biologically active in inducing skipping of myostatin exon 2 and dystrophin exon 23, 
respectively10, were purchased from GeneTools (Philomath, Oregon, USA). The PMOs were 
then conjugated to an arginine-rich cell-penetrating peptide (B-peptide: RXRRBRRXRRBRXB) 
at the 3’-end of the PMO as previously described28. BPMOs were dissolved in sterile ddH2O and 
were diluted in sterile 0.9% saline (Sigma, Dorset, UK) at a desired concentration immediately 
prior to an injection. 
 
Animals and experimental design 
 
Animal work was performed in accordance with the UK Animals (Scientific Procedures) Act, 
1986. Mdx (C57BL/10ScSn-Dmdmdx) and C57BL/10 mice were bred in house and were 
maintained in a standard 12-hour light/dark cycle with free access to food and water. Mice were 
weaned at weeks 4-5 postnatal and were housed 3-6 individuals per cage. Since only males 
were used, mice within each experimental group were obtained randomly from two litters. The 
experiment included three mdx groups receiving either 10 mg/kg BPMO-DMD (n = 7), a 
combination of 10 mg/kg BPMO-DMD and 10 mg/kg BPMO-MSTN (n = 6), or volume-matched 
sterile saline (Sigma, Dorset, UK), (n = 4); and one C57 group injected with volume-matched 
sterile saline (n = 5) acted as a control. Intraperitoneal injections were administered at day 0, 
week 3, and week 6 of animal age. All mice were sacrificed at week 9.  
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Muscle tissue collection  
 
Mice were sacrificed by exposure to a rising concentration of CO2. From each mouse, the 
diaphragm - DIA, the extensor digitorum longus - EDL, the gastrocnemius - GAS, the soleus - 
SOL, and the tibialis anterior - TA were collected. Tissue from one side of the body was frozen 
immediately in liquid nitrogen for RNA and protein extraction whilst tissue from the other side 
was embedded in optimal cutting temperature medium (VWR, Leicestershire, UK) and 
subsequently frozen in liquid nitrogen-cooled isopentane (Sigma, Dorset, UK) for sectioning. All 
samples were kept at -80oC until use.  
 
RNA extraction and RT-PCR analyzing exon skipping efficiency  
 
RNeasy Fibrous Tissue kits (QIAgen, Manchester, UK) were used in RNA extraction. Muscle 
tissue was homogenized in the lysis buffer provided with the kit at 20 Hz for 2 min, twice, using 
a TissueLyser II (QIAgen, Manchester, UK). The total RNA was then extracted following the 
manufacturer's instructions. RNA quantification was performed on a ND-1000 NanoDrop 
spectrophotometer (Thermo Scientific, Leicestershire, UK). Five-hundred nanograms of 
extracted RNA were reverse transcribed by GeneScript RT-PCR kit (GeneSys Ltd, Surrey, UK) 
and resulting cDNA samples were then amplified through RT-PCRs. Two microlitres of RT-PCR 
products were used as templates in subsequent semi-nested (dystrophin exon skipping) or 
nested (myostatin exon skipping) PCRs. The final PCR products were then loaded onto 2% 
agarose gels. HyperLadder IV (Bioline, London, UK) was used as a size standard. 
Densitometric analysis of gel electrophoresis results was performed using GeneTools Image 
Analysis software 4.02 (Syngene, Cambridge, UK). The efficiency of dystrophin or myostatin 
exon skipping was evaluated as a percentage of the density of skipped products against the 
total density of unskipped and skipped products. RT-PCRs were performed in duplicate. Details 
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of PCR programs and sequence of primers (MWG, Ebersberg, Germany) are available on 
request. 
 
Protein extraction and Western Blotting quantifying dystrophin expression 
 
Muscle tissue was homogenized in lysis buffer (0.15M NaCl, 0.05M HEPES, 1% NP-40, 0.5% 
Sodium deoxycholate, 0.1% SDS, 0.01M EDTA) containing protease inhibitors (Roche, 
Hertfordshire, UK) at 25 Hz for 2 min, twice, on a TissueLyser II (QIAgen, Manchester, UK). The 
supernatant, after centrifugation at 13,000 rpm/5 min/4oC, was transferred to fresh pre-chilled 
1.5 ml tubes. Quantifying the total protein was performed by DCTM Protein Assay (Bio-Rad, 
Hertfordshire, UK) following the manufacturer's instructions. Thirty micrograms total protein from 
C57 samples or 150 µg total protein from mdx samples were resolved on 3-8% Tris Acetate 
NuPage gels (Life Technologies, Paisley, UK). HiMark Pre-stained Protein Ladder (Life 
Technologies, Paisley, UK) was used as a size standard. The gels were run at 150V for 1.5 h 
then transferred to HyBond nitrocellulose membranes (GE Healthcare, Little Chalfont, UK) at 
30V for 2 h. Protein transfer efficiency was immediately checked with Ponceau S staining. 
Membranes were then blocked in blocking buffer (1X PBS, 0.05% Tween 20, 5% skimmed milk) 
for 1 h, at room temperature. An overnight incubation at 4oC with either monoclonal mouse anti-
dystrophin 6C5 (1:100, Novocastra Laboratories, Newcastle upon Tyne, UK) or rabbit anti-α-
tubulin (1:2500, Abcam, Cambridge, UK) antibody was carried out. After 3 washes in 1X PBS/ 
0.05% Tween 20 (1X PBS-T), the membranes were incubated with corresponding secondary 
antibody (1:10000, LI-COR Biosciences, Cambridge, UK), either goat anti-mouse IRDye800 or 
goat anti-rabbit IRDye680. Western blot results were visualized on an Odyssey Infrared Imaging 
System (LI-COR Biosciences, Cambridge, UK). Densitometric analysis of dystrophin- and α-
tubulin-positive patterns was evaluated using ImageJ software (NIH, Bethesda, Maryland, USA). 
The value of dystrophin intensity was then normalized to the value of corresponding α-tubulin 
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intensity and was displayed as a percentage of the value of C57 samples obtained in the same 
way (considered as 100%). Reagents were purchased from Sigma (Dorset, UK), unless stated 
otherwise. 
 
Muscle sectioning and immunohistochemical analysis 
 
Tissue was cryo-sectioned on an OTF 5000 cryostat (Bright, Huntingdon, UK) at 10 µm 
thickness through the muscle length. Transverse sections were then fixed in ice-cold acetone 
and blocked in PBS containing 1% BSA, 1% goat serum, and 0.1% Triton X-100. Sections were 
subsequently incubated with rat anti-laminin antibody (1:1000, Sigma, Dorset, UK) at 4oC, 
overnight. Three washes in 1X PBS-T were completed prior to an incubation with goat anti-rat 
Alexa568 (1:1000, Life Biotechnologies, Paisley, UK) in 1X PBS-T/1% goat serum for 1 h. 
Subsequent dystrophin staining using Mouse-on-Mouse Fluorescein kit (Vector Laboratory, 
Peterborough, UK) was carried out following the manufacturer's instructions. Primary antibody 
was monoclonal mouse anti-dystrophin 6C5 (1:50, Novocastra Laboratories, Newcastle upon 
Tyne, UK) and secondary antibody was goat anti-mouse Alexa488 (1:1000, Life 
Biotechnologies, Paisley, UK). An additional 15-min staining with 1 µg/ml DAPI (4′,6-diamidino-
2-phenylindole, Sigma, Dorset, UK) in 1X PBS-T/1% goat serum was performed. Sections were 
then mounted in Mowiol 4-88 medium (Sigma, Dorset, UK). 
 
Cell image capture 
 
Muscle sections were visualized under an inverted fluorescence Axio Observer D1 microscope. 
Single images were captured by an AxioCam MR3. These images were then used for fiber 
analysis or were automatically overlapped and stitched by AxioVision software to generate a 
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mosaic image of each section. Equipment and software were purchased from Carl Zeiss 
(Cambridge, UK). 
 
Histological analysis 
 
Laminin staining (see previous section for materials and method) was used to identify the fiber 
perimeter. Incomplete fibers touching the edge of the image field were excluded. Semi-
automatic quantification of the minimal Ferret's diameter of fibers was performed by ImageJ 
software (NIH, Bethesda, Maryland, USA). The variance coefficient of minimal Ferret's diameter 
from each section was then calculated as the ratio between the standard deviation (x1000) and 
the mean of the diameter, and was expressed as arbitrary units. The number of fibers having 
internal nuclei within each section was counted manually and expressed as percentage of the 
total fiber number within that section.    
 
Statistical analysis 
 
Data were analyzed by GraphPad Prism5 software (San Diego, California, USA) and shown as 
the means ± S.E.M; error bars represent the S.E.M; “n” refers to the number of mice per group. 
Comparisons of statistical significance were assessed by one-way ANOVA followed by 
Bonferroni's post-hoc test or by two-tailed Student’s t-test. Significant levels were set at *p < 
0.05, **p < 0.01, ***p < 0.001.  
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Figure legends 
 
Fig. 1: Confirming BPMO-induced dystrophin and myostatin exon skipping through RT-
PCRs. Neonatal mdx were injected with BPMO-DMD (10 mg/kg, n = 7) or a cocktail of BPMO-
DMD & BPMO-MSTN (10 mg/kg each BPMO, n = 6). Intraperitoneal injection was performed on 
day 0 and was repeated every three weeks afterwards. Mice were sacrificed at week 9. Total 
RNA from the diaphragm (DIA), extensor digitorum longus (EDL), gastrocnemius (GAS), soleus 
(SOL), and tibialis anterior (TA) was excised and RNA extracted for semi-nested dystrophin RT-
PCRs or nested myostatin RT-PCRs. (a) Levels of dystrophin exon skipping within individual 
muscles and (b) an average of dystrophin exon skipping from five muscles are displayed. (c) 
Efficiency of myostatin exon skipping from five examined muscles and as an average of those 
values (body). The efficiency of dystrophin or myostatin exon skipping was evaluated through 
densitometric analysis of RT-PCR products as a percentage of the density of skipped products 
against the density of both skipped and unskipped products. Results shown in (a-c) were from 
two separate RT-PCRs. Data are expressed as means ± S.E.M; error bars represent the S.E.M. 
Statistical analysis in a, b was performed by two-tailed Student’s t-test with no significant 
difference was detected. (d, e) Representative RT-PCR products demonstrate dystrophin and 
myostatin exon skipping, respectively. PCR products were loaded onto 2% agarose gel; each 
lane displays the result from individual mouse; HyperLadder IV was used as a molecular size 
standard. Exons included in PCR product bands shown to the left of each gel  
 
Fig. 2: Western blotting demonstrates a recovery in dystrophin expression of treated 
mdx mice. Following i.p. administration (at day 0, weeks 3 and 6) of BPMO-DMD (10 mg/kg, n 
= 7) or a cocktail of BPMO-DMD & BPMO-MSTN (10 mg/kg each BPMO, n = 6), the diaphragm 
(DIA), gastrocnemius (GAS), and tibialis anterior (TA) were excised at week 9. Proteins from 
these muscles were then extracted. (a) Expression of dystrophin (dys+) was confirmed by 
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Western blot analysis. Each lane represents a sample from an individual mouse. Proteins from 
muscle type-matched of saline-injected C57 and mdx were loaded as positive and negative 
controls, respectively. Alpha-tubulin (α-tub+) was used as an internal loading control for Western 
blot. (b) An evaluation of dystrophin levels expressed in the diaphragm. Following a 
densitometric analysis, the intensity of dys+ patterns was normalized to the intensity of 
corresponding α-tub+ patterns; the results were expressed as a percentage of the value from 
C57 sample obtained in the same way (which was considered as 100%). Data are shown as 
means ± S.E.M, with error bars representing the S.E.M. Statistical comparison was analyzed by 
two-tailed Student's t test.  
 
Fig. 3: Dystrophin expression within skeletal muscle sections is ascertained by 
immunohistochemistry staining. Mdx neonates were injected (i.p) with BPMO-DMD (10 
mg/kg, n = 7), a cocktail of BPMO-DMD & BPMO-MSTN (10 mg/kg each BPMO, n = 6), or 
volume-matched sterile saline (n = 4); a group of C57 (n = 5) receiving i.p injection of saline was 
used as a positive control. The injection was performed every 3 weeks. Muscles were collected 
at week 9 and were subsequently sliced at 10 µm thickness. Representative mosaic images 
demonstrating dystrophin expression from BPMO-injected mdx or C57 muscles are shown as in 
groups of treatment. Cell images at higher magnification are shown in top-left insets at scale bar 
= 50 µm. Dystrophin-positive fibers were stained in green. Nuclei were stained in blue with 
DAPI. DIA: diaphragm, EDL: extensor digitorum longus, GAS: gastrocnemius, SOL: soleus, TA: 
tibialis anterior. 
 
Fig. 4: Effects of antisense therapy on diaphragm and soleus muscles. Either BPMO-DMD 
(n = 7) or a cocktail of BPMO-DMD and BPMO-MSTN (n = 6) was administered into mdx 
neonates at day 0, weeks 3 and 6. Following the same procedure, volume-matched saline was 
injected into another mdx group for negative control (n = 4) and into a C57 group for positive 
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control (n = 5). At week 9 of age, muscles were harvested and sectioned at 10 µm thickness. 
Representative cell images from (a) diaphragm and (f) soleus sections are shown respectively. 
Laminin-positive fibers were stained in red whilst dystrophin-positive fibers were stained in 
green. Nuclei were stained in blue with DAPI. Scale bar = 50 µm. (b, g) Results from analysis of 
frequency distribution of the minimal Feret’s diameter and (c, h) the variance coefficient of the 
Feret’s diameter are displayed in turn for diaphragm and soleus fibers, as arbitrary units. (d, i) 
The total number of fibers and (e, j) the prevalence of centronucleated fibers (as percentage of 
the total fiber number) within each section of (d, e) the diaphragm or (i, j) the soleus are shown. 
Data are expressed as means ± S.E.M, with error bars representing the S.E.M. Significant 
differences were assessed by one-way ANOVA followed by Bonferroni’s post-hoc test; 
Significant levels were set at *p < 0.05, **p < 0.01, ***p < 0.001.   
 
Fig. 5: Effects of AO treatment on body and muscle mass. Neonatal mice received three i.p 
injections on day 0, week 3, and week 6. Mdx were injected with either BPMO-DMD (10 mg/kg, 
n = 7) or a cocktail of BPMO-DMD & BPMO-MSTN (10 mg/kg each BPMO, n = 6); another 
group of mdx (n = 4) and a group of C57 (n = 5) neonates injected with volume-matched sterile 
saline acted as negative and positive controls, respectively. (a) Body weight assessed every two 
weeks is shown. (b) The weight at each two-week time was then normalized to the birth weight. 
(c) Animals were sacrificed 3 weeks after the last injection; muscle mass of the diaphragm 
(DIA), extensor digitorum longus (EDL), gastrocnemius (GAS), soleus (SOL), and tibialis 
anterior (TA) is displayed. (d) Muscle mass was normalized to corresponding final body mass. 
Data are expressed as means ± S.E.M, with error bars representing the S.E.M. Statistical 
analysis was performed by one-way ANOVA followed by Bonferroni’s post-hoc test. Significant 
levels were set at *p < 0.05, **p < 0.01, ***p < 0.001. 
 





